Publication | Closed Access

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

Phase 3GynecologyMenopausal Hormone TherapyMenopausePharmacotherapySkylight 1Hormone TherapyPostreproductive HealthEndocrinologyMedicineModerate-to-severe Vasomotor SymptomsMenstrual CycleWomen's HealthHormone Replacement TherapyMenopause Hormone Therapy